期刊文献+
共找到1,677篇文章
< 1 2 84 >
每页显示 20 50 100
Glucocorticoid therapy in pancreatic portal hypertension associated with autoimmune pancreatitis:A case report
1
作者 Yi Zhang Zhao-Dong Li +3 位作者 Yuan-Jing He Wei Peng Yu-Jun Luo Xiao-An Li 《World Journal of Clinical Cases》 SCIE 2024年第22期5184-5188,共5页
BACKGROUND Autoimmune pancreatitis(AIP)is a chronic form of pancreatitis characterized by diffused enlargement of the pancreas and irregular stenosis of the main pancreatic duct.Some studies have reported that AIP can... BACKGROUND Autoimmune pancreatitis(AIP)is a chronic form of pancreatitis characterized by diffused enlargement of the pancreas and irregular stenosis of the main pancreatic duct.Some studies have reported that AIP can cause hemorrhage of gastric varices(GV)related to portal hypertension(PH).However,such cases are rare.In addition,the association of PH with AIP is unclear.At the same time,the efficacy and duration of glucocorticoid therapy is also controversial.CASE SUMMARY In this case,we reported a case of GV in pancreatic PH associated with AIP.Enhanced abdominal computed tomography(CT)suggested splenic vein(SV)and superior mesenteric vein(SMV)thromboses.The patient received a long-term glucocorticoid therapy,that the initial dose of 40 mg is reduced weekly by 5 mg,and then reduced to 5 mg for long-term maintenance.CT and gastroscopic examination after 8 mo of treatment indicated that SV and SMV were recanalized,pancreatic stiffness and swelling were ameliorated,and the GV almost completely disappeared.CONCLUSION Long-term glucocorticoid therapy can alleviate the development of GV in patients with AIP and has potential reversibility. 展开更多
关键词 Autoimmune pancreatitis Pancreatic portal hypertension Gastric varices Glucocorticoid therapy Case report
下载PDF
宫颈癌调强计划Portal Dosimetry剂量验证中拼接野的应用分析
2
作者 时飞跃 吕懂霞 +5 位作者 付林 庄洁颖 王敏 秦伟 赵环宇 魏晓为 《中国医疗设备》 2024年第10期73-78,共6页
目的提出一种生成Portal Dosimetry(以下简称PD)分野的拼接野(以下简称PD拼接野)方法,并对宫颈癌计划的PD拼接野进行分析研究。方法选取20例宫颈癌患者的七野调强治疗计划进行研究,治疗计划中每个大野分成1对分野。首先制作仅含分野的P... 目的提出一种生成Portal Dosimetry(以下简称PD)分野的拼接野(以下简称PD拼接野)方法,并对宫颈癌计划的PD拼接野进行分析研究。方法选取20例宫颈癌患者的七野调强治疗计划进行研究,治疗计划中每个大野分成1对分野。首先制作仅含分野的PD剂量验证计划,然后使用直线加速器出束执行。通过矩阵拼接和矩阵叠加,分别得到每对PD分野对应的PD拼接野和PD大野。使用PD软件模块,得到PD拼接野和PD大野的伽玛通过率,分别记为Gp和Gd。使用Gm表示每对PD分野的平均伽玛通过率值。对Gp、Gd和Gm进行统计分析和比较研究。结果所有140个射野的Gp、Gd和Gm的值分别为98.78%±0.70%、97.34%±1.25%和98.87%±0.51%。两两比较结果显示,Gp和Gd差异具有统计学意义(P<0.05);Gp和Gm的数据差异较小。对每个PD验证计划,计算所有同一类射野对应的计划验证通过率(Gplan)。对Gplan数据进行统计分析显示,PD拼接野和PD大野差异具有统计学意义(P<0.05),PD拼接野和PD分野的数据差异较小。结论本文提出的PD拼接野概念为评价PD剂量验证结果提供了有益的参考信息。 展开更多
关键词 宫颈癌 分野 拼接野 伽玛通过率 portal Dosimetry 调强放射治疗 矩阵拼接
下载PDF
Liver transplantation and resection in patients with hepatocellular cancer and portal vein tumor thrombosis: Feasible and effective? 被引量:3
3
作者 Prashant Bhangui 《Hepatobiliary & Pancreatic Diseases International》 SCIE CAS CSCD 2024年第2期123-128,共6页
Patients with locally advanced hepatocellular cancer(HCC)and portal vein tumor thrombosis(PVTT)have a dismal prognosis since limited treatment options are available for them.In recent years,effective systemic therapy,... Patients with locally advanced hepatocellular cancer(HCC)and portal vein tumor thrombosis(PVTT)have a dismal prognosis since limited treatment options are available for them.In recent years,effective systemic therapy,and advances in the understanding of technicalities and effectiveness of ablative therapies especially radiotherapy,have given some hope to prolong survival in them.This review summarized recent evidence in literature regarding the possible role of liver resection(LR)and liver transplantation(LT)in patients with locally advanced HCC and PVTT with no extrahepatic disease.Downstaging therapies have helped make curative resection or LT a reality in selected patients.This review emphasizes on the key points to focus on when considering surgery in these patients,who are usually relegated to palliative systemic therapy alone.Meticulous patient selection based on tumor biology,documented downstaging based on imaging and decrease in tumor marker levels,and an adequate waiting period to demonstrate stable disease,may help obtain satisfactory long-term outcomes post LR or LT in an intention to treat strategy in patients with HCC and PVTT. 展开更多
关键词 Hepatocellular carcinoma portal vein tumour thrombosis Downstaging therapies Living donor liver transplantation and resection OUTCOMES
下载PDF
Contemporary concepts of the medical therapy of portal hypertension under liver cirrhosis 被引量:18
4
作者 Dmitry Victorovich Garbuzenko 《World Journal of Gastroenterology》 SCIE CAS 2015年第20期6117-6126,共10页
Severe complications of liver cirrhosis are mostly related to portal hypertension. At the base of the pathogenesis of portal hypertension is the increase in hepatic vascular resistance to portal blood flow with subseq... Severe complications of liver cirrhosis are mostly related to portal hypertension. At the base of the pathogenesis of portal hypertension is the increase in hepatic vascular resistance to portal blood flow with subsequent development of hyperdynamic circulation, which, despite of the formation of collateral circulation, promotes progression of portal hypertension. An important role in its pathogenesis is played by the rearrangement of vascular bed and angiogenesis. As a result, strategic directions of the therapy of portal hypertension under liver cirrhosis include selectively decreasing hepatic vascular resistance with preserving or increasing portal blood flow, and correcting hyperdynamic circulation and pathological angiogenesis, while striving to reduce the hepatic venous pressure gradient to less than 12 mm Hg or 20% of the baseline. Over the last years, substantial progress in understanding the pathophysiological mechanisms of hemodynamic disorders under liver cirrhosis has resulted in the development of new drugs for their correction. Although the majority of them have so far been investigated only in animal experiments, as well as at the molecular and cellular level, it might be expected that the introduction of the new methods in clinical practice will increase the efficacy of the conservative approach to the prophylaxis and treatment of portal hypertension complications. The purpose of the review is to describe the known methods of portal hypertension pharmacotherapy and discuss the drugs that may affect the basic pathogenetic mechanisms of its development. 展开更多
关键词 Liver CIRRHOSIS portal HYPERTENSION PATHOGENESIS Medical therapy
下载PDF
Antiangiogenic therapy for portal hypertension in liver cirrhosis: Current progress and perspectives 被引量:13
5
作者 Dmitry Victorovich Garbuzenko Nikolay Olegovich Arefyev Evgeniy Leonidovich Kazachkov 《World Journal of Gastroenterology》 SCIE CAS 2018年第33期3738-3748,共11页
Developing medicines for hemodynamic disorders that are characteristic of cirrhosis of the liver is a relevant problem in modern hepatology. The increase in hepatic vascular resistance to portal blood flow and subsequ... Developing medicines for hemodynamic disorders that are characteristic of cirrhosis of the liver is a relevant problem in modern hepatology. The increase in hepatic vascular resistance to portal blood flow and subsequent hyperdynamic circulation underlie portal hypertension(PH) and promote its progression, despite the formation of portosystemic collaterals. Angiogenesis and vascular bed restructurization play an important role in PH pathogenesis as well. In this regard, strategic directions in the therapy for PH in cirrhosis include selectively decreasing hepatic vascular resistance while preserving or increasing portal blood flow, and correcting hyperdynamic circulation and pathological angiogenesis. The aim of this review is to describe the mechanisms of angiogenesis in PH and the methods of antiangiogenic therapy. The Pub Med database, the Google Scholar retrieval system, and the reference lists from related articles were used to search for relevant publications. Articles corresponding to the aim of the review were selected for 2000-2017 using the keywords: "liver cirrhosis", "portal hypertension", "pathogenesis", "angiogenesis", and "antiangiogenic therapy". Antiangiogenic therapy for PH was the inclusion criterion. In this review, we have described angiogenesis inhibitors and their mechanism of action in relation to PH. Although most of them were studie donly in animal experiments, this selective therapy for abnormally growing newly formed vessels is pathogenetically reasonable to treat PH and associated complications. 展开更多
关键词 Liver CIRRHOSIS portal hypertension PATHOGENESIS ANGIOGENESIS ANTIANGIOGENIC therapy
下载PDF
Anticoagulation therapy prevents portal-splenic vein thrombosis after splenectomy with gastroesophageal devascularization 被引量:47
6
作者 Wei Lai Shi-Chun Lu +5 位作者 Guan-Yin Li Chuan-Yun Li Ju-Shan Wu Qing-Liang Guo Meng-Long Wang Ning Li 《World Journal of Gastroenterology》 SCIE CAS CSCD 2012年第26期3443-3450,共8页
AIM:To compare the incidence of early portal or splenic vein thrombosis(PSVT) in patients treated with irregular and regular anticoagulantion after splenectomy with gastroesophageal devascularization.METHODS:We retros... AIM:To compare the incidence of early portal or splenic vein thrombosis(PSVT) in patients treated with irregular and regular anticoagulantion after splenectomy with gastroesophageal devascularization.METHODS:We retrospectively analyzed 301 patients who underwent splenectomy with gastroesophageal devascularization for portal hypertension due to cirrhosis between April 2004 and July 2010.Patients were categorized into group A with irregular anticoagulation and group B with regular anticoagulation,respectively.Group A(153 patients) received anticoagulant monotherapy for an undesignated time period or with aspirin or warfarin without low-molecular-weight heparin(LMWH) irregularly.Group B(148 patients) received subcutaneous injection of LMWH routinely within the first 5 d after surgery,followed by oral warfarin and aspirin for one month regularly.The target prothrombin time/international normalized ratio(PT/INR) was 1.25-1.50.Platelet and PT/INR were monitored.Color Doppler imaging was performed to monitor PSVT as well as the effectiveness of thrombolytic therapy.RESULTS:The patients' data were collected and analyzed retrospectively.Among the patients,94 developed early postoperative mural PSVT,including 63 patients in group A(63/153,41.17%) and 31 patients in group B(31/148,20.94%).There were 50(32.67%) patients in group A and 27(18.24%) in group B with mural PSVT in the main trunk of portal vein.After the administration of thrombolytic,anticoagulant and antiaggregation therapy,complete or partial thrombus dissolution achieved in 50(79.37%) in group A and 26(83.87%) in group B.CONCLUSION:Regular anticoagulation therapy can reduce the incidence of PSVT in patients who undergo splenectomy with gastroesophageal devascularization,and regular anticoagulant therapy is safer and more effective than irregular anticoagulant therapy.Early and timely thrombolytic therapy is imperative and feasible for the prevention of PSVT. 展开更多
关键词 portal vein hypertension Splenectomy withgastroesophageal devascularization portal or splenicvein thrombosis Anticoagulation regimen Thrombo-lyric therapy
下载PDF
Portal hypertension: Imaging of portosystemic collateral pathways and associated image-guided therapy 被引量:16
7
作者 Murad Feroz Bandali Anirudh Mirakhur +4 位作者 Edward Wolfgang Lee Mollie Clarke Ferris David James Sadler Robin Ritchie Gray Jason Kam Wong 《World Journal of Gastroenterology》 SCIE CAS 2017年第10期1735-1746,共12页
Portal hypertension is a common clinical syndrome, defined by a pathologic increase in the portal venous pressure. Increased resistance to portal blood flow, the primary factor in the pathophysiology of portal hyperte... Portal hypertension is a common clinical syndrome, defined by a pathologic increase in the portal venous pressure. Increased resistance to portal blood flow, the primary factor in the pathophysiology of portal hypertension, is in part due to morphological changes occurring in chronic liver diseases. This results in rerouting of blood flow away from the liver through collateral pathways to low-pressure systemic veins. Through a variety of computed tomographic, sonographic, magnetic resonance imaging and angiographic examples, this article discusses the appearances and prevalence of both common and less common portosystemic collateral channels in the thorax and abdomen. A brief overview of established interventional radiologic techniques for treatment of portal hypertension will also be provided. Awareness of the various imaging manifestations of portal hypertension can be helpful for assessing overall prognosis and planning proper management. 展开更多
关键词 portal hypertension Diagnostic imaging Portosystemic collaterals Image-guided therapy
下载PDF
Radiation therapy for portal venous invasion by hepatocellular carcinoma 被引量:14
8
作者 Keiichi Nakagawa Hideomi Yamashita +8 位作者 Kenshiro Shiraishi Naoki Nakamura Masao Tago Hiroshi Igaki Yoshio Hosoi Shuichiro Shiina Masao Omata Masatoshi Makuuchi Kuni Ohtomo 《World Journal of Gastroenterology》 SCIE CAS CSCD 2005年第46期7237-7241,共5页
AIM: To darify bhe efficacy and safety of bhree-dimensional conformal radiotherapy (3-D CRT) for bhis disease and to specify patient subgroups suitable for this treatment. METHODS: Fifty-two patients with HCC rece... AIM: To darify bhe efficacy and safety of bhree-dimensional conformal radiotherapy (3-D CRT) for bhis disease and to specify patient subgroups suitable for this treatment. METHODS: Fifty-two patients with HCC received PVItargeted radiation therapy from .January 1995 through December 2003. Portal venous invasion (PVI) was found in the second or lower order branches of the portal vein in 6 patients, in the first branch in 24 patients and in the main trunk in 22 patients. Child classifications of liver function before radiation therapy were A, B, and C for 19, 24 and 2 patients, respectively. All patients received three-dimensional conformal radiotherapy with a total dose ranging from 39 to 60 Gy (57.0 Gy in average). RESULTS: Overall survival rates at 1, 2, 3, 4, and 5 years were 45.1%, 25.3%, 15.2%, 10.1%, and 5.1%, respectively. Univariate analysis revealed that Child status, the number of tumor foci, tumor type, transcatheter arterial embolization (TAE) after radiation therapy were statistically significant prognostic factors. Multivariate analysis showed that the number of tumor foci and TAE after radiation therapy were statistically significant. CONCLUSION: The results of this study strongly suggest the efficacy of 3-D CRT as treatment for PVI in HCC. 3-D CRT is recommended in combination with postradiation TAE for PVI of HCC with 5 tumor foci or less in the liver and with Child A liver function. 展开更多
关键词 Hepatocellular carcinoma portal venous invasion Radiation therapy
下载PDF
Transjugular intrahepatic portosystemic shunt and splenectomy are more effective than endoscopic therapy for recurrent variceal bleeding in patients with idiopathic noncirrhotic portal hypertension 被引量:8
9
作者 Fu-Liang He Rui-Zhao Qi +6 位作者 Yue-Ning Zhang Ke Zhang Yu-Zheng Zhu-Ge Min Wang Yu Wang Ji-Dong Jia Fu-Quan Liu 《World Journal of Clinical Cases》 SCIE 2020年第10期1871-1877,共7页
BACKGROUND Transjugular intrahepatic portosystemic shunt(TIPS),splenectomy plus esophagogastric devascularization(SED)and endoscopic therapy+non-selectiveβ-blockers(ET+NSBB)are widely applied in secondary prevention ... BACKGROUND Transjugular intrahepatic portosystemic shunt(TIPS),splenectomy plus esophagogastric devascularization(SED)and endoscopic therapy+non-selectiveβ-blockers(ET+NSBB)are widely applied in secondary prevention of recurrent gastroesophageal variceal bleeding in patients with liver cirrhosis.These different treatments,however,have not been compared in patients with idiopathic noncirrhotic portal hypertension(INCPH).AIM To compare the outcomes of TIPS,SED and ET+NSBB in the control of variceal rebleeding in patients with INCPH.METHODS This retrospective study recruited patients from six centers across China.Demographic characteristics,baseline profiles and follow-up clinical outcomes were collected.Post-procedural clinical outcomes,including incidence of rebleeding,hepatic encephalopathy(HE),portal vein thrombosis(PVT)and mortality rates,were compared in the different groups.RESULTS In total,81 patients were recruited,with 28 receiving TIPS,26 SED,and 27 ET+NSBB.No significant differences in demographic and baseline characteristics were found among these three groups before the procedures.After treatment,blood ammonia was significantly higher in the TIPS group;hemoglobin level and platelet count were significantly higher in the SED group(P<0.01).Rebleeding rate was significantly higher in the ET+NSBB group(P<0.01).Mortality was 3.6%,3.8%and 14.8%in the TIPS,SED and ET+NSBB groups,respectively,with no significant differences(P=0.082).Logistic regression analysis showed that mortality was significantly correlated with rebleeding,HE,portal thrombosis and superior mesenteric vein thrombosis(P<0.05).CONCLUSION In patients with INCPH,TIPS and SED were more effective in controlling rebleeding than ET+NSBB,but survival rates were not significantly different among the three groups.Mortality was significantly correlated with rebleeding,HE and PVT. 展开更多
关键词 Idiopathic non-cirrhotic portal hypertension Transjugular intrahepatic portosystemic shunt Splenectomy plus esophagogastric devascularization Endoscopic therapy SURVIVAL
下载PDF
Portal vein stenosis after pancreatectomy following neoadjuvant chemoradiation therapy for pancreatic cancer
10
作者 Yosuke Tsuruga Hirofumi Kamachi +4 位作者 Kenji Wakayama Tatsuhiko Kakisaka Hideki Yokoo Toshiya Kamiyama Akinobu Taketomi 《World Journal of Gastroenterology》 SCIE CAS 2013年第16期2569-2573,共5页
Extrahepatic portal vein (PV) stenosis has various causes, such as tumor encasement, pancreatitis and as a postsurgical complication. With regard to post-pancreaticoduodenectomy, intraoperative radiation therapy with/... Extrahepatic portal vein (PV) stenosis has various causes, such as tumor encasement, pancreatitis and as a postsurgical complication. With regard to post-pancreaticoduodenectomy, intraoperative radiation therapy with/ without PV resection is reported to be associated with PV stenosis. However, there has been no report of PV stenosis after pancreatectomy following neoadjuvant chemoradiation therapy (NACRT). Here we report the cases of three patients with PV stenosis after pancreatectomy and PV resection following gemcitabine-based NACRT for pancreatic cancer and their successful treatment with stent placement. We have performed NACRT in 18 patients with borderline resectable pancreatic cancer since 2005. Of the 15 patients who completed NACRT, nine had undergone pancreatectomy. Combined portal resection was performed in eight of the nine patients. We report here three patients with PV stenosis, and thus the ratio of post-operative PV stenosis in patients with PV resection following NACRT is 37.5% in this series. We encountered no case of PV stenosis among 22 patients operated with PV resection for pancreatobiliary cancer without NACRT during the same period. A relationship between PV stenosis and NACRT is suspected, but further investigation is required to determine whether NACRT has relevance to PV stenosis. 展开更多
关键词 Pancreatic cancer portal VEIN STENOSIS NEOADJUVANT CHEMORADIATION therapy PANCREATECTOMY EXPANDABLE metallic stent
下载PDF
Clinical Effects of the Qi-acupuncture Therapy of TCM on Portal Hypertension 被引量:1
11
作者 XU Yu-bo LIU Xiang 《World Journal of Integrated Traditional and Western Medicine》 2020年第7期1-9,共9页
Objective:To explore the effective prevention and treatment of portal hypertension(PH).Methods:A total of 220 patients who came to our hospital from March 2015 to October 2018 were treated.They were randomly divided i... Objective:To explore the effective prevention and treatment of portal hypertension(PH).Methods:A total of 220 patients who came to our hospital from March 2015 to October 2018 were treated.They were randomly divided into the treatment group and the control group,each with 110 cases.Before treatment,there was no significant differences in age,sex,clinical symptoms,signs,laboratory tests and color Doppler ultrasound related examinations between the 2 groups(P>0.05).Among them,the treatment group on the basis of traditional Chinese and Western medicine treatment in our hospital,the Qi-acupuncture therapy of TCM was added.The extra meridian acupoints along with acupoints were selected.The control group received conventional treatment with traditional Chinese and Western medicine in our hospital.Results:There were significant differences in clinical symptoms,signs and chemistry between groups after treatment(P<0.01).There were significant differences in test,color ultrasound related examination and so on(P<0.01).Those in the treatment group was significantly better than the control group(P<0.01).Conclusion:On the basis of the Qi-acupuncture therapy of TCM,selecting extra meridian acupoint and acupoints can effectively treat PH. 展开更多
关键词 portal hypertension CIRRHOSIS Qi-acupuncture therapy of TCM ACUPUNCTURE
下载PDF
肝移植围手术期门静脉血栓管理的研究进展
12
作者 吕少诚 贺强 《器官移植》 CSCD 北大核心 2024年第1期26-32,共7页
门静脉血栓是肝硬化的常见并发症之一,其发生率随着疾病的发展而增加。门静脉血栓的发生发展与多种因素有关,抗凝治疗的指征仍需进一步研究探索。门静脉血栓目前已不再认为是肝移植手术的禁忌,但是复杂的门静脉血栓会增加肝移植围手术... 门静脉血栓是肝硬化的常见并发症之一,其发生率随着疾病的发展而增加。门静脉血栓的发生发展与多种因素有关,抗凝治疗的指征仍需进一步研究探索。门静脉血栓目前已不再认为是肝移植手术的禁忌,但是复杂的门静脉血栓会增加肝移植围手术期风险,如何恢复门静脉系统血流是临床手术方案决策的难点,合理的术前分型、手术规划和门静脉重建方式是保障肝移植受者远期良好预后的关键。本文就门静脉血栓的流行病学现状、危险因素、分型与鉴别,肝移植术前门静脉血栓管理和术中处理,以及门静脉血栓对肝移植结局的影响进行综述,为肝移植围手术期门静脉血栓的管理提供参考。 展开更多
关键词 肝移植 门静脉血栓 分型 血管重建 抗凝治疗 溶栓治疗 经颈静脉肝内门体静脉分流术 出血
下载PDF
mFOLFOX7化疗方案联合卡瑞利珠单抗和阿帕替尼治疗CNLCⅢ期肝细胞癌有效性和安全性的前瞻性研究
13
作者 彭林辉 陈涛 +8 位作者 徐云修修 王捷 陈捷 李永 黄拼搏 钟国平 陈茜 叶聪婷 陈亚进 《岭南现代临床外科》 2024年第1期1-6,共6页
目的探索静脉mFOLFOX7化疗方案联合卡瑞利珠单抗和阿帕替尼在CNLCⅢ期肝细胞癌中的有效性及安全性(NCT05412589)。方法本研究为单臂、开放、前瞻性临床研究,计划入组35例未经治疗的CNLCⅢ期肝细胞癌患者。主要研究终点为基于RECIST 1.1... 目的探索静脉mFOLFOX7化疗方案联合卡瑞利珠单抗和阿帕替尼在CNLCⅢ期肝细胞癌中的有效性及安全性(NCT05412589)。方法本研究为单臂、开放、前瞻性临床研究,计划入组35例未经治疗的CNLCⅢ期肝细胞癌患者。主要研究终点为基于RECIST 1.1标准评估的客观缓解率(ORR),次要研究终点包括:基于mRECIST标准评估的ORR,和基于RECIST 1.1标准和mRECIST标准评估的疾病控制率(DCR)、无进展生存时间(PFS),以及总生存时间(OS)、手术转化率、治疗相关不良反应(TRAE)等。结果收集并分析2021年4月至2023年4月期间符合入排标准并签署同意书入组的26例肝细胞癌患者资料。中位随访时间为13个月,ORR为61.5%(RECIST v1.1)和73.1%(mRECIST),临床缓解率为26.9%,病理完全缓解率为23.1%,DCR为96.2%,mPFS和mOS均尚未达到,均超过9个月。手术转化率为57.7%,均实现R0切除。TRAE≥3级不良事件发生率为50%。结论静脉mFOLFOX7化疗方案联合卡瑞利珠单抗和阿帕替尼是治疗CNLCⅢ期肝细胞癌的一种有效、安全、易行的策略,初步研究效果类似于FOLFOX⁃HAIC联合靶免治疗。 展开更多
关键词 肝细胞癌 门静脉主干癌栓 全身化疗 免疫检查点抑制剂 抗血管生成靶向药物
下载PDF
肝硬化门静脉血栓形成诊治新进展
14
作者 张明 《实用肝脏病杂志》 CAS 2024年第1期11-15,共5页
门静脉血栓形成(portal vein thrombosis,PVT)被定义为门静脉主干或其分支内血栓形成,伴或不伴延伸至脾静脉或/和肠系膜上静脉的栓子[1,2]。PVT的出现给肝硬化患者后续治疗,不论是急性出血、腹水还是肝移植,都带来更多技术上的困难。因... 门静脉血栓形成(portal vein thrombosis,PVT)被定义为门静脉主干或其分支内血栓形成,伴或不伴延伸至脾静脉或/和肠系膜上静脉的栓子[1,2]。PVT的出现给肝硬化患者后续治疗,不论是急性出血、腹水还是肝移植,都带来更多技术上的困难。因为PVT的存在可导致肝门静脉灌注减少和实质萎缩,还可导致门静脉高压进一步加重和肝功能恶化,发生失代偿事件和死亡的风险也显著增加,影响预后[3]。这类患者发生急性食管胃静脉曲张时,控制急性出血失败的风险较无PVT者增加3倍。在规律内镜治疗过程中,消除静脉曲张的时间也更长。本文就肝硬化并发PVT做一介绍,供相关专业医生参考。 展开更多
关键词 肝硬化 门静脉血栓形成 抗凝治疗 经颈静脉肝内门体分流术
下载PDF
TIPSS术使用组合支架与Viatorr支架治疗肝硬化并发门静脉高压症患者长期疗效比较
15
作者 鲍应军 张媛 +5 位作者 顾俊鹏 朱帝文 张海潇 曹耿飞 阿斯哈尔·哈斯木 任伟新 《实用肝脏病杂志》 CAS 2024年第4期583-586,共4页
目的探讨经颈静脉肝内门体静脉分流术(TIPSS)中使用组合支架与Viatorr支架的长期疗效。方法2013年7月~2022年8月新疆医科大学第一附属医院介入治疗中心诊治的肝硬化并发门静脉高压症患者51例,均接受TIPSS术治疗,其中使用组合支架29例,使... 目的探讨经颈静脉肝内门体静脉分流术(TIPSS)中使用组合支架与Viatorr支架的长期疗效。方法2013年7月~2022年8月新疆医科大学第一附属医院介入治疗中心诊治的肝硬化并发门静脉高压症患者51例,均接受TIPSS术治疗,其中使用组合支架29例,使用Viatorr支架22例。术后随访5年。使用影像学检查肝内分流道通畅情况,应用Kaplan-Meler法分析比较两组分流道累积通畅率和生存率。结果使用Viatorr支架手术花费为73282.9(68190.6,81242.2)元,显著高于使用组合支架【61912.7(53713.6,67530.3)元,P<0.05】;第一年、二年、三年、四年和五年,Viatorr支架组肝内分流道累积通畅率分别为90.9%、77.3%、72.7%、71.4%和68.4%,组合支架组分别为86.7%、80.0%、76.7%、73.3%和70.0%,两组无统计学差异(P>0.05);Viatorr支架组累计生存率分别为95.5%、77.3%、72.7%、68.2%和59.1%,组合支架组分别为93.3%、86.7%、83.3%、83.3%和79.9%,两组无统计学差异(P>0.05)。结论本组资料显示,在行TIPSS手术时使用组合支架或Viatorr支架均可获得较好的临床效果,可根据供给情况选择使用。 展开更多
关键词 肝硬化 门脉高压症 经颈静脉肝内门体静脉分流术 组合支架 Viatorr支架 治疗
下载PDF
肝移植术后严重门静脉狭窄的三维可视化成像与门静脉支架植入术疗效分析
16
作者 赵洪强 刘影 +7 位作者 马建明 李昂 于里涵 童翾 吴广东 卢倩 张跃伟 汤睿 《器官移植》 CSCD 北大核心 2024年第1期82-89,共8页
目的分析肝移植术后严重门静脉狭窄的三维成像特征与优势,评估门静脉支架植入术效果。方法回顾性分析10例肝移植术后因严重门静脉狭窄接受门静脉支架植入的患者的临床资料,分析严重门静脉狭窄的影像学特征、三维重建的成像优势及介入治... 目的分析肝移植术后严重门静脉狭窄的三维成像特征与优势,评估门静脉支架植入术效果。方法回顾性分析10例肝移植术后因严重门静脉狭窄接受门静脉支架植入的患者的临床资料,分析严重门静脉狭窄的影像学特征、三维重建的成像优势及介入治疗效果。结果10例患者中狭窄类型包括向心性缩窄3例,曲折成角致狭窄2例,受压狭窄2例,长段狭窄和(或)血管闭塞3例。三维重建图像在狭窄的准确判断、狭窄类型的辨别和狭窄累及长度判断方面具有优势。所有患者均成功接受门静脉支架植入术,支架植入后门静脉最狭窄处直径较治疗前增加[(6.2±0.9)mm比(2.6±1.7)mm,P<0.05],吻合口流速较治疗前下降[(57±19)cm/s比(128±27)cm/s,P<0.05],近肝处门静脉主干流速较治疗前增加[(41±6)cm/s比(18±6)cm/s,P<0.05]。1例患者因介入穿刺引起肝内血肿,经保守观察治疗后好转,其余患者均未出现相关并发症。结论三维可视化技术可以立体直观展示狭窄部位、特征与严重程度,有利于临床医师进行治疗决策和辅助介入操作。及时的门静脉支架植入术可以有效逆转病变进程并改善门静脉血流。 展开更多
关键词 肝移植 血管并发症 门静脉狭窄 介入治疗 三维可视化成像 门静脉支架 血流加速 门静脉高压
下载PDF
肝硬化门静脉血栓形成风险监测及抗凝管理 被引量:1
17
作者 靳珂珂 丁惠国 《实用肝脏病杂志》 CAS 2024年第1期3-6,共4页
门静脉血栓形成(portal vein thrombosis,PVT)指形成于门静脉主干、肝内门静脉分支、肠系膜静脉或脾静脉的血栓[1]。PVT是肝硬化患者常见且严重的并发症之一。失代偿期肝硬化患者PVT患病率高于代偿期肝硬化患者(9.36%对5.24%,P=0.04),并... 门静脉血栓形成(portal vein thrombosis,PVT)指形成于门静脉主干、肝内门静脉分支、肠系膜静脉或脾静脉的血栓[1]。PVT是肝硬化患者常见且严重的并发症之一。失代偿期肝硬化患者PVT患病率高于代偿期肝硬化患者(9.36%对5.24%,P=0.04),并发PVT者发生静脉曲张破裂出血(EVB)的比例显著高于无PVT者(47.33%对19.63%,P<0.001)[2]。当肝移植患者并发血栓延伸至肠系膜上静脉(superior mesenteric vein,SMV)时,术后病死率增加[3]。PVT形成会影响肝脏血流,增加门静脉压力,进而可能增加EVB、腹水、肠缺血坏死等临床并发症的风险。但是,关于肝硬化并发PVT形成的危险因素、对门静脉高压相关并发症、肝病进展和病死率的影响仍未完全阐明,肝硬化并发PVT患者的风险监测及抗凝治疗仍有待进一步研究。 展开更多
关键词 肝硬化 门静脉血栓形成 危险因素 抗凝治疗
下载PDF
内镜下曲张静脉套扎术联合经颈静脉肝内门体静脉分流术治疗肝硬化食管胃底静脉曲张破裂出血患者效果研究 被引量:1
18
作者 肖潇 盛云建 《实用肝脏病杂志》 CAS 2024年第2期238-241,共4页
目的观察采用内镜下曲张静脉套扎术(EVL)联合经颈静脉肝内门体静脉分流术(TIPS)治疗肝硬化并发食管胃底静脉曲张破裂出血(EVB)患者的效果。方法2019年3月~2022年1月我院收治的85例肝硬化并发EVB患者,其中42例对照组接受EVL术治疗,43例... 目的观察采用内镜下曲张静脉套扎术(EVL)联合经颈静脉肝内门体静脉分流术(TIPS)治疗肝硬化并发食管胃底静脉曲张破裂出血(EVB)患者的效果。方法2019年3月~2022年1月我院收治的85例肝硬化并发EVB患者,其中42例对照组接受EVL术治疗,43例观察组在接受EVL治疗后择期行TIPS治疗。随访6个月。采用超声检测门静脉压力梯度(PPG)、门静脉压力(PVP)和门静脉血流速度(PVFV),采用ELISA法检测血清过氧化脂质(LPO)、胃动素(MTL)和胃泌素(GAS)水平。结果急性期,观察组和对照组病死率分别为9.3%和9.5%(P>0.05);两组止血时间和输血量无显著性差异(P>0.05),而观察组住院日为(12.8±2.6)d,显著长于对照组【(8.1±1.5)d,P<0.05】;术后,观察组PVFV为(16.7±3.8)cm/s,显著快于对照组【(12.5±2.4),P<0.05】,而PPG和PVP分别为(9.1±1.4)mmHg和(19.6±2.3)mmHg,均显著低于对照组【分别为(12.2±1.9)mmHg和(34.8±3.4)mmHg,P<0.05】;观察组血清LPO、MTL和GAS水平分别为(4.1±2.2)U/L、(202.4±22.7)ng/L和(76.3±8.4)μg/mL,均显著低于对照组【分别为(7.9±1.6)U/L、(256.8±26.1)ng/L和(115.6±10.9)μg/mL,P<0.05】;随访6个月,对照组和观察组再出血发生率分别为31.6%和7.7%(P<0.05)。结论在实施EVL急性期止血后适时进行TIPS术治疗肝硬化并发EVB患者效果确切,可减少再出血发生率,值得进一步研究。 展开更多
关键词 肝硬化 食管胃底静脉曲张破裂出血 曲张静脉套扎术 经颈静脉肝内门体静脉分流术 再出血 治疗
下载PDF
合并大血管侵犯的原发性肝细胞癌病人外放射治疗进展
19
作者 陈理丹 姚沛 段华新 《安徽医药》 CAS 2024年第1期16-21,共6页
原发性肝细胞癌(HCC)病人确诊时常发现合并大血管侵犯(MVI),如门静脉瘤栓(PVTT)、肝静脉瘤栓(HVTT)及下腔静脉瘤栓(IVCTT)等。而大血管侵犯常预示着病人预后欠佳。目前可供选择的治疗方式多样,但缺少对伴有大血管侵犯的HCC治疗的专家共... 原发性肝细胞癌(HCC)病人确诊时常发现合并大血管侵犯(MVI),如门静脉瘤栓(PVTT)、肝静脉瘤栓(HVTT)及下腔静脉瘤栓(IVCTT)等。而大血管侵犯常预示着病人预后欠佳。目前可供选择的治疗方式多样,但缺少对伴有大血管侵犯的HCC治疗的专家共识。随着外放射治疗技术的发展,外放射治疗已成为HCC合并大血管侵犯的重要治疗手段之一。因此,现针对外放射治疗在合并大血管侵犯的肝细胞癌中的应用情况进行总结,以期为合并大血管侵犯的肝癌病人提供更多的治疗选择。 展开更多
关键词 肝细胞 放射疗法 调强适形 质子疗法 门静脉瘤栓 肝静脉瘤栓
下载PDF
Yttrium-90 radioembolization treatment strategies for management of hepatocellular carcinoma
20
作者 Kelly Hao Andrew J Paik +1 位作者 Lauren H Han Mina S Makary 《World Journal of Radiology》 2024年第10期512-527,共16页
As the third leading cause of cancer-related deaths worldwide,hepatocellular carcinoma(HCC)represents a significant global health challenge.This paper provides an introduction and comprehensive review of transarterial... As the third leading cause of cancer-related deaths worldwide,hepatocellular carcinoma(HCC)represents a significant global health challenge.This paper provides an introduction and comprehensive review of transarterial radioembolization(TARE)with Yttrium-90(Y90),a widely performed transcatheter procedure for HCC patients who are not suitable candidates for surgery.TARE involves the targeted delivery of radioactive microspheres to liver tumors,offering a promising treatment option for managing HCC across various stages of the disease.By evaluating Y90 TARE outcomes across early,intermediate,and advanced stages of HCC,the review aims to present a thorough understanding of its efficacy and safety.Additionally,this paper highlights future research directions focusing on the potential of combination therapies with systemic and immunotherapies,as well as personalized treatments.The exploration of these innovative approaches aims to improve treatment outcomes,reduce adverse events,and provide new therapeutic opportunities for HCC patients.The review underscores the importance of ongoing research and clinical trials to optimize TARE further and integrate it into comprehensive HCC treatment paradigms. 展开更多
关键词 Transarterial radioembolization Hepatocellular carcinoma Yttrium-90 Radiation segmentectomy Radiation lobectomy portal vein thrombosis Combination therapies Downstaging Curative-intent Locoregional therapy
下载PDF
上一页 1 2 84 下一页 到第
使用帮助 返回顶部